Posts

Posted on

Farmland Partners Sells 862-Acre Arkansas Farm

Farmland Partners Sells 862-Acre Arkansas Farm

DENVER–(BUSINESS WIRE)–
Farmland Partners Inc. (NYSE: FPI) (the “Company” or “FPI”) today announced that it sold 862 acres of farmland in White County, Arkansas, for $3.7 million – an approximate gain of 24% over net book value.

“The farmland real estate sector is still open for business. We continue to hunt for prime land to acquire, and we are always willing to entertain strong offers for existing properties in our portfolio,” explained Luca Fabbri, FPI’s President and CEO. “Sales like this one allow us to capture asset appreciation for our shareholders and redeploy capital.”

FPI sold the land to a local farmer who owns a nearby cotton gin and plans to grow cotton on the property. As part of the transaction, FPI will retain all the solar energy option payments currently being made on the tract and will retain a 30% interest in future revenue created if the renewable energy project enters construction during the option period.

After the disposition, the Company’s footprint in Arkansas totals nearly 12,000 acres.

About Farmland Partners Inc.

Farmland Partners Inc. is an internally managed real estate company that owns and seeks to acquire high-quality North American farmland and makes loans to farmers secured by farm real estate. As of the date of this release, the Company owns and/or manages nearly 195,000 acres in 19 states, including Alabama, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana, Michigan, Mississippi, Missouri, Nebraska, North Carolina, South Carolina, Texas, and Virginia. In addition, FPI owns land and buildings for four agriculture equipment dealerships in Ohio leased to Ag Pro under the John Deere brand. We have approximately 26 crop types and over 100 tenants. The Company elected to be taxed as a real estate investment trust, or REIT, for U.S. federal income tax purposes, commencing with the taxable year ended December 31, 2014. Additional information: www.farmlandpartners.com or (720) 452-3100.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the federal securities laws, including, without limitation, statements with respect to our outlook and the outlook for the farm economy generally, proposed and pending acquisitions and dispositions, financing activities, crop yields and prices and anticipated rental rates. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” or similar expressions or their negatives, as well as statements in future tense. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, beliefs and expectations, such forward-looking statements are not predictions of future events or guarantees of future performance and our actual results could differ materially from those set forth in the forward-looking statements. Some factors that might cause such a difference include the following: the on-going war in Ukraine and its impact on the world agriculture market, world food supply, the farm economy, and our tenants’ businesses; general volatility of the capital markets and the market price of the Company’s common stock; changes in the Company’s business strategy, availability, terms and deployment of capital; the Company’s ability to refinance existing indebtedness at or prior to maturity on favorable terms, or at all; availability of qualified personnel; changes in the Company’s industry, interest rates or the general economy; adverse developments related to crop yields or crop prices; the degree and nature of the Company’s competition; the timing, price or amount of repurchases, if any, under the Company’s share repurchase program; the ability to consummate acquisitions or dispositions under contract; and the other factors described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and the Company’s other filings with the Securities and Exchange Commission. Any forward-looking information presented herein is made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

Phillip Hayes

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Agriculture Construction & Property Natural Resources REIT

MEDIA:

Logo
Logo
Posted on

Flora Growth Receives CGMP Certification of Compound Formulation Lab; Launches Prescription Cannabis Medicines in Colombia

Flora Growth Receives CGMP Certification of Compound Formulation Lab; Launches Prescription Cannabis Medicines in Colombia

  • Flora Growth (NASDAQ: FLGC) receives INVIMA Current Good Manufacturing Practices (CGMP) certification for Flora Lab 4, a compound prescription formulation lab, based in Bogotá, Colombia

  • The company will release eight prescription cannabis formulations to address specific ailments

  • Flora’s formulations will begin being prescribed by doctors in Colombia and will be fully covered by all Colombian insurers

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading cultivator, manufacturer and distributor of global cannabis products and brands, announced today the certification of its Bogotá-based compound formulation laboratory, Flora Lab 4, following the required regulatory inspection by INVIMA (Colombia’s FDA). The inspection certifies the lab as meeting Current Good Manufacturing Practices standards as determined by INVIMA. Flora Lab 4 specializes in manufacturing compound formulations utilizing cannabis derivatives and traditional master formulas.

Flora Lab 4 will now begin offering its cannabis formulations as well as design, development and manufacturing services for third parties. The lab will also make available to clients its experienced team members, knowledge of cannabis and modern facilities to promote the growth of the medical cannabis sector.

To begin, the team has developed eight cannabis-based formulations, in both topical and ingestible formats, specially designed to aid in the treatment of specific ailments, including various skin conditions, multiple sclerosis, anxiety and dementia. The team hopes to gather patient-reported pilot-study data to better understand patient responses and outcomes.

“We are very pleased to have received CGMP certification and to bring effective medicinal cannabis treatments to patients in Colombia. We applaud the Colombian government’s acknowledgment of the power of this plant by requiring all health insurance providers to cover the cost of medical cannabis. This policy is fundamental to fair access to these medicines for Colombia’s roughly 30 million eligible patients,” said Luis Merchan, Chairman and CEO of Flora. “At Flora, we know the future of cannabis relies heavily on the transformation of this unique plant into mainstream medicines, accessible to the populations who need it most. We are proud to be playing a leading role in the progress toward that goal.”

With the approval from INVIMA, cannabis medicines can now be accessed by doctor networks throughout Colombia and can immediately be prescribed to patients over the age of 18. This offering comes as a law that went into effect on January 1, 2023, requires all insurance providers in the country to cover the cost of medical cannabis treatments for patients.

Flora is committed to creating sustainable growth in its Pharmaceutical division by utilizing high-quality raw materials sourced from its cannabis cultivation and processing operations in Colombia. These materials are then used for applied research initiatives in medical cannabis, contributing to the development of innovative and effective pharmaceutical products that can be used around the world. By ensuring the quality of its raw materials, Flora Lab 4 can confidently pursue its goal of advancing the medical cannabis industry and improving the lives of patients in need.

About Flora Growth Corp.

Flora Growth Corp. is a global cannabis company dedicated to bringing the benefits of cannabis to people worldwide. Our commitment is to create, master and connect the international cannabis supply chain by setting the standard for world-class cultivation and manufacturing, thoughtful brand development, and rigorous research and development of medical-grade cannabis products that meet the highest standards of quality, safety, and efficacy. Our mission is to create a world where the benefits of cannabis are accessible to everyone, and we are working toward that goal by becoming a leading importer and exporter of cannabis to meet demand in every corner of the market. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains ‘‘forward-looking statements,’’ as defined by federal securities laws. Forward-looking statements reflect Flora’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in Flora’s Annual Report on Form 20-F filed with the SEC on May 9, 2022, as such factors may be updated from time to time in Flora’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora’s filings with the SEC. While forward-looking statements reflect Flora’s good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Flora (or to third parties making the forward-looking statements).

Investor Relations:

[email protected]

Public Relations:

Cassandra Dowell

+1 (858) 221-8001

[email protected]

KEYWORDS: Florida United States South America Colombia North America

INDUSTRY KEYWORDS: Alternative Medicine Cannabis Health Natural Resources General Health Research Science

MEDIA:

Posted on

Colliers Issues Notice of Redemption for Convertible Notes

TORONTO, April 04, 2023 (GLOBE NEWSWIRE) —  Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers”) announced today that it has issued a notice of redemption to all holders of its previously issued 4.00% convertible senior subordinated notes due 2025 (the “Convertible Notes”). As at the date hereof, US$230 million of principal amount is outstanding pursuant to the Convertible Notes.

The applicable redemption date shall be June 1, 2023 (the “Redemption Date”), and Colliers will, in accordance with the terms and conditions of the indenture governing the Convertible Notes, satisfy its obligations in connection with any redeemed Convertible Notes by issuing an amount of subordinate voting shares (“Shares”) per US$1,000 of redeemed principal amount that is calculated based on the average of daily volume-weighted average trading prices of the Shares for the thirty trading day period ending on May 24, 2023. All accrued but unpaid interest on any redeemed amounts for the period up to but excluding the Redemption Date will be paid in cash.

Prior to 5:00 p.m. (Eastern time) on May 31, 2023, holders of Convertible Notes will have the right to convert into Shares at a conversion rate of 17.7607 Shares per US$1,000 of principal amount, which is equivalent to a conversion price of approximately US$56.30 per Share.

No fractional shares will be issued upon any redemption or conversion, and Colliers shall satisfy any fractional shares by way of cash payment in accordance with the terms of the indenture governing the Convertible Notes.

Holders of Convertible Notes are encouraged to consult their applicable financial institution to obtain advice regarding the redemption or conversion process.

This press release does not constitute an offer to sell or a solicitation to buy any of the securities described herein, nor shall there be any offer, solicitation, or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Colliers 

Colliers (NASDAQ, TSX: CIGI) is a leading diversified professional services and investment management company. With operations in 65 countries, our 18,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 28 years, our experienced leadership with significant inside ownership has delivered compound annual investment returns of approximately 20% for shareholders. With annual revenues of $4.5 billion and $98 billion of assets under management, Colliers maximizes the potential of property and real assets to accelerate the success of our clients, our investors, and our people. Learn more at corporate.colliers.com, Twitter @Colliers or LinkedIn.

Forward-looking Statements

This press release includes or may include forward-looking statements, including regarding redemption of the Convertible Notes. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results, performance or achievements contemplated in the forward-looking statements. Such factors include the risk factors identified in the Company’s other periodic filings with Canadian and US securities regulators, including the Company’s most recently filed annual information form which is available on SEDAR at www.sedar.com and is filed with the Company’s most recently filed annual report on Form 40-F and is available on EDGAR at www.sec.gov. Forward looking statements contained in this press release are made as of the date hereof and are subject to change. All forward-looking statements in this press release are qualified by these cautionary statements. Except as required by applicable law, Colliers undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Christian Mayer
Chief Financial Officer
(416) 960-9500



Posted on

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., April 04, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 124,300 shares, and restricted stock units (RSUs) covering an aggregate of 40,350 shares, of BioCryst common stock. The options and RSUs were granted as of March 31, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $8.34 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW


Contact:


John Bluth
+1 919 859 7910
[email protected]



Posted on

ChampionX Announces First Quarter 2023 Earnings Release and Conference Call Schedule

THE WOODLANDS, Texas, April 04, 2023 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today that it will release its first quarter 2023 operating results on Monday, April 24, 2023, after the market closes. The Company has scheduled a conference call for Tuesday, April 25, 2023, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss the results.

The call will be available by live webcast on ChampionX’s website at https://investors.championx.com or by dialing in as follows:

  United States: 1-888-396-8049
  International: 1-416-764-8646
  Reference: ChampionX conference call ID: 40158679

Please register for the webcast or dial into the call approximately 15 minutes prior to the scheduled start time.

A replay of the conference call will be available for 30 days on ChampionX’s website.

About ChampionX

ChampionX is a global leader in chemistry solutions, artificial lift systems, and highly engineered equipment and technologies that help companies drill for and produce oil and gas safely, efficiently, and sustainably around the world. ChampionX’s expertise, innovative products, and digital technologies provide enhanced oil and gas production, transportation, and real-time emissions monitoring throughout the lifecycle of a well. To learn more about ChampionX, visit our website at www.championX.com.

Investor Contact:
Byron Pope – [email protected] – 281-602-0094

Media Contact:
John Breed – [email protected] – 281-403-3751



Posted on

ZeroFox Enhances Executive Protection Offering with PII Removal

Updated solution includes multiple tiers of protection, hardens customers’ attack surface and reduces breach risk by removing online personal information used to target executives

WASHINGTON, April 04, 2023 (GLOBE NEWSWIRE) — ZeroFox (Nasdaq: ZFOX), a leading external cybersecurity provider, today announced enhancements to its Executive Protection solution designed to safeguard executives, VIPs, and other high-value targets from physical and cyber threats. The new ZeroFox Executive Protection Premium offering now includes PII Removal service and expands coverage for up to five family members.

Executive Protection Premium addresses four primary areas of concern:

  • Preventing threat actors from exploiting executive reputation and influence through social media impersonations, account takeovers, and phishing attacks
  • Detection and removal of exposed personal information on data broker sites
  • Protecting executives from physical threats and disruptive global events at home, office, or travel locations
  • Expanding coverage to the attack surface for up to five family members at five different physical locations

Executive impersonations are only increasing; ZeroFox’s latest Executive Protection Threat Landscape Report showed a 26.2% increase in impersonations and a 29% spike in scams, fraud, and piracy targeting the C-suite and VIPs between 2021 and 2022. With the addition of PII Removal, a disruption service that automates the removal of personal identifiable information (PII) listed for sale on publicly searchable databases and data broker sites, executives can have peace of mind for themselves and those closest to them with protection from impersonations, targeted attacks, harassment, and scams.

“As cybercriminals and their methods of attack grow more sophisticated, executives have become a top target as an entry point into an organization,” said James C. Foster, chairman and CEO of ZeroFox. “ZeroFox excels at detecting and removing executive impersonations and personal information across the entire external attack surface – we had 485,190 successful PII Removals in 2022 – and we’re proud to expand our protection of executives to keep them, their company, and those closest to them safe from external cyber threats.”

To learn more about our enhanced Executive Protection offerings and how to keep your VIPs safe, visit here.

ZeroFox Contacts:

Media Inquiries
Malory Van Guilder
[email protected]

Investor Relations
Marc P. Griffin, ICR
[email protected]



Posted on

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.

The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled “Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035. The patent claims a fundamental design for steerable introducer sheaths, such as those used for BioCardia’s autologous and allogeneic cell therapy procedures, and for transseptal procedures for the treatment of cardiac arrhythmias. The design enables the tensioning elements in the catheter to rotate around the catheter shaft, allowing consistent catheter performance in any direction. This design is intended to enable smooth navigation and prevent “whip,” when a catheter in the heart suddenly jumps from one orientation to another due to the build-up of mechanical forces in the device. This patented design is incorporated in the Company’s FDA-cleared Morph DNA™ product, a 5 French sheath equivalent, and in the Company’s FDA-cleared Avance™ product, an 8.5 French introducer sheath indicated for transseptal procedures.

The Indian Patent Office granted the Company Patent Number 424579, entitled “Steerable Endoluminal Devices and Methods for Use,” with a patent term that will expire in late 2031. The patent claims a fundamental design for steerable introducer sheaths. The design is for a coil with a braid disposed coaxially about the coil, all embedded within the wall of an introducer sheath. The coil enables a robust, kink-resistant design with enhanced column support, while the braid in the catheter shaft provides for excellent torque transmission. This patent design feature has demonstrated excellent performance in the Company’s Morph Access Pro™ product family and has been used to treat approximately 10,000 patients to-date, ranging from a two-year-old girl to a 90-year-old man.

“This positive experience with the Morph DNA, Avance, and Morph AccessPro underlies our understanding of catheter navigation that informs the delivery of our higher-value biotherapeutic interventions, where we utilize steerable guide sheaths in every procedure,” said BioCardia CEO Peter Altman, PhD. “The acquisitions of Baylis by Boston Scientific for $1.5 billion and the acquisition of the Acutus sheath portfolio by Medtronic for $87 million last year were focused on enabling transseptal access devices, like these, that enable ablation therapies to treat cardiac arrhythmias. These acquisitions show that these steerable catheter assets are nontrivial to develop and that the intellectual property that underlies these assets has the potential to enable large market opportunities and be quite valuable.”

These new patents are anticipated to strengthen the protection of BioCardia’s efforts with respect to its cardiovascular therapeutic approaches and provide enhanced value for all therapies developed with the Helix biotherapeutic delivery system product family.

ABOUT BIOCARDIA

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP™ autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial also has CMS Reimbursement. The Company’s current products include the Helix™ Transendocardial Biotherapeutic Delivery System, which it partners selectively with other biotherapeutic companies requiring local delivery to the heart. For more information visit: www.BioCardia.com.

FORWARD LOOKING STATEMENTS 

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to development and value of steerable access catheter products and intellectual property and statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter into licensing and partnering arrangements, and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

 We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled “Risk Factors.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact:

Anne Laluc, Marketing
Email: [email protected]
Phone: 650-226-0120

Investor Contact:

David McClung, Chief Financial Officer
Email: [email protected]
Phone: 650-226-0120



Posted on

Alta Equipment Group Announces Preferred Stock Dividend

LIVONIA, Mich., April 04, 2023 (GLOBE NEWSWIRE) — Alta Equipment Group Inc. (NYSE: ALTG) (“Alta”), a leading provider of premium material handling, construction and environmental processing equipment and related services, today announced that its Board of Directors approved the quarterly dividend on its Series A Cumulative Perpetual Preferred Stock in the amount of $625 per preferred share. This will equate to a dividend of $0.625 for each of the outstanding Depositary Shares representing a 1/1000th fractional interest in one share of Series A Preferred. The dividend payment date is May 1, 2023, to shareholders of record at the close of business on April 15, 2023.

About Alta Equipment Group Inc.

Alta owns and operates one of the largest integrated equipment dealership platforms in the U.S. and have a presence in Canada. Through its branch network, the Company sells, rents, and provides parts and service support for several categories of specialized equipment, including lift trucks and aerial work platforms, cranes, earthmoving equipment, environmental processing equipment and other material handling and construction equipment. Alta has operated as an equipment dealership for 38 years and has developed a branch network that includes over 70 total locations across Michigan, Illinois, Indiana, New England, New York, Virginia, Nevada, Florida and Ohio as well as the Canadian provinces of Ontario and Quebec. Alta offers its customers a one-stop-shop for their equipment needs through its broad, industry-leading product portfolio. More information can be found at www.altaequipment.com.

Contacts

Investors:

Kevin Inda
SCR Partners, LLC
[email protected]
(225) 772-0254

Media:

Glenn Moore
Alta Equipment
[email protected]
(248) 305-2134



Posted on

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET.

Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting large and growing patient populations.

Later this year, Oculis is expecting Stage 1 results from its Phase 3 DIAMOND study of OCS-01, a topical eye drop in DME and results from its Phase 3 OPTIMIZE study of OCS-01 for the treatment of inflammation and pain following cataract surgery. Furthermore, in the coming months, Oculis plans on initiating two Phase 2 studies with OCS-02, a topical anti-TNF alpha monoclonal antibody fragment, in DED and in chronic anterior uveitis.

During the event, Oculis’ management team will provide an overview of the Company’s key development and late-stage pipeline. In addition, retina experts Arshad M. Khanani, MD (USA) and Pravin Dugel, MD, (USA), and anterior segment ophthalmologist, Eric Donnenfeld, MD (USA), will be present to answer clinical questions during the live Q&A session.

A live audio webcast of the event and accompanying slides will be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. To access the live event online, please pre-register for the webcast here. To access the live event by phone, please pre-register for the conference call here. A replay of the webcast will be available for 30 days following the event.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop retinal candidate for diabetic macular edema (DME); OCS-02, a topical eye drop biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Contacts

Investor Relations

Riad Sherif, MD, CEO
[email protected]

Ms. Sylvia Cheung, CFO
[email protected]

Media Relations

Consilium Strategic Communications
Amber Fennell, Tracy Cheung, David Daley
[email protected]

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward looking statements and information. For example, statements regarding expected future milestones and catalysts; the initiation, timing, progress and results of Oculis’ clinical and preclinical studies; Oculis’ research and development programs, regulatory and business strategy, future development plans, and management; Oculis’ ability to advance product candidates into, and successfully complete, clinical trials; and the timing or likelihood of regulatory filings and approvals, are forward looking. All forward looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ proxy statement and the prospectus for Oculis’ offering, and any other documents filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.



Posted on

Manitoba Harvest Expands Whole Foods Market Distribution

Natural Foods Industry Leaders Reinforce Commitment to Healthy Living and Environmental Sustainability with the Launch of ROC™ Hemp Hearts and the Largest Regenerative Hemp Harvest in the World

NEW YORK and WINNIPEG, Manitoba, April 04, 2023 (GLOBE NEWSWIRE) — Manitoba Harvest, the world’s leading hemp foods brand and a wholly-owned subsidiary of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), debuts the brand’s first Regenerative Organic Certified™ (ROC™) Hemp Hearts exclusively at select Whole Foods Market stores across the United States beginning in April 2023. Following the exclusivity period, the product will continue to be available at Whole Foods Market and other locations throughout the U.S. and Canada.

Jared Simon, President at Manitoba Harvest, said, “We are thrilled to expand our distribution with Whole Foods Market with the launch of Manitoba Harvest Regenerative Organic Certified™ Hemp Hearts as consumer interest in hemp-based foods continues to grow. Over the past year, products with hemp as an ingredient grew 1.5x faster than products with chia and flax, other leading super seeds1. As Hemp industry leaders, we’re committed to educating consumers about the vast nutritional, sustainable and versatile benefits of hemp by bringing best-in-class products to market.”

Vanessa Nguyen-Lanau, Assistant Category Merchant for Global Whole Body, Whole Foods Market, said, “Whole Foods Market is excited to bring customers a new, nutrition-packed and regenerative staple from Manitoba Harvest. Manitoba Harvest consistently delivers products that align with our customer’s lifestyle and values, and we’re excited to introduce a product that furthers our commitment to good stewardship of our environment.”

With 10g of plant protein and 12g of omegas 3 & 6 per serving, Manitoba Harvest ROC™ Hemp Hearts are an ultimate super food with a versatile, nutty flavor and vital nutrients for daily wellness like magnesium, fiber, zinc, and iron. Hemp Hearts are great for a range of dietary preferences including Vegan, Paleo, Keto, and Gluten-Free diets.

As a Certified B Corporation and brand dedicated to fostering a healthy and sustainable environment, Manitoba Harvest ROC™ Hemp Hearts take an active role in combating climate change by supporting soil health. To do this, Manitoba Harvest partners with organic farmers who work to restore degraded soil, improve biodiversity, increase carbon capture, and improve their livelihoods. Hemp is ideal for regenerative agriculture because of its deep roots and pest resilience. It also helps replenish carbon in the soil, supports living root systems, reduces the use of pesticides, and sequesters carbon. Regenerative Organic Certification also prioritizes the well-being of farming communities. For 25 years, Manitoba Harvest has supported indigenous and local farming communities by providing hemp agronomy training to improve yields and enhance financial stability.

About Manitoba Harvest

Manitoba Harvest is a pioneer and leader in branded hemp-based foods, and is recognized as a Certified B Corporation and the first Canadian food company to attain a Carbonzero Certification.

Taking the seed-to-shelf approach since 1998, Manitoba Harvest is committed to quality, sustainability, and consumer wellness. With an extensive product portfolio of Hemp Hearts (shelled hemp seed), Hemp Protein, Hemp Protein Blends, Hemp Wellness Bars, Hemp Granola, and Hemp Oil, Manitoba Harvest products are sold globally and in approximately 17,000 retail stores across North America.

To learn more about Manitoba Harvest and shop, visit www.manitobaharvest.com and follow @manitobaharvest across all social platforms.

About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering a worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Tilray’s mission is to be the most responsible, trusted, and market-leading cannabis and consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we open a world of well-being, visit www.Tilray.com and follow @tilray on all social platforms.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information:

Media:
Berrin Noorata, [email protected]
Investors:
Raphael Gross, (203) 682-8253, [email protected]

______________________
1 Source: Total US Combined Channels, Total Frozen, Refrigerated, & Grocery Departments, TPL Universe, L52 Weeks ending 10/30/22

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/999275f3-8192-4e6e-b63f-1487d92fae02